

LARGE CLINICAL EXPERIENCE  
**+400 MILLION**  
PATIENT DAYS  
EU APPROVED  
BIOSIMILAR MEDICINES

2006



1<sup>st</sup> WORLDWIDE APPROVAL  
IN THE EU



BIOSIMILAR FILGRASTIM

**+44%** PATIENT ACCESS  
IN THE EU (2006 - 2013)



AVAILABLE TO PATIENTS  
IN **+60 COUNTRIES**  
AROUND THE WORLD

A GROWING OPPORTUNITY  
FOR HEALTHCARE BUDGETS

A **€78 BN** MARKET  
WILL OPEN TO  
COMPETITION BY 2020 



1<sup>st</sup> BIOSIMILAR MONOCLONAL  
ANTIBODY  
EU - 2013

USE OF BIOSIMILARS

SAVINGS FROM  
**€11,8** UP TO **33,4 BN**  
FOR 8 EU COUNTRIES (2007-2020)

OVER **15** EUROPEAN COUNTRIES  
HAVE MANUFACTURING SITES FOR  
BIOSIMILAR MEDICINES  
OR BIOSIMILAR  
CANDIDATES UNDER  
DEVELOPMENT/EVALUATION 